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Cancer is becoming an increasingly common disease in which abnormal cells aggressively grow, invade, and metastasize. In this
paper, we review the biological functions of PEDF (pigmented epithelium-derived factor) against cancer, with a focus on a partic-
ular type of bone cancer called osteosarcoma. PEDF is a 50kDa glycoprotein and is a potent inhibitor of angiogenesis, via its ability
to decrease proliferation and migration of endothelial cells. This paper critically examines the anticancer activities of PEDF via its
role in antiangiogenesis, apoptosis-mediated tumor suppression, and increased tumor cell diﬀerentiation. Recently, an orthotopic
model of osteosarcoma was used to show that treatment with PEDF had the greatest impact on metastases, warranting an
evaluation of PEDF eﬃcacy in other types of cancers.
1.Introduction
Cancer is characterized by uncontrolled growth and spread
of cells harboring some form of genetic aberration. Forma-
tion of tumours requires sequential acquisition of defects
that endow tumour cells with the ability to grow, invade, and
eventually metastasize. Even after signiﬁcant improvements
in surgery, chemotherapy, and radiotherapy, there are still
numerous tumours that are unaﬀected by therapy. By
the time a tumour is diagnosed, it has almost certainly
begun metastasizing. In such cases radiation therapy and
chemotherapy are often used in combination with surgery
in the hope that the tumour and its metastases are eﬀectively
controlled [1]. Targeted biological therapies, which are safer,
are being studied and clinical trials are conducted to gauge
eﬃcacy. The main objective of targeted therapy is to attack
speciﬁc pathways and tumour growth mechanisms without
the side eﬀects attached to small molecule drugs and
radiotherapy [2, 3].
PEDF is a 50-kDa glycoprotein, which is a member of the
serine protease inhibitor (serpin) family, and it has multi-
functional properties [4]. It is found to be a potent inhibitor
of angiogenesis, proliferation and migration of endothelial
cells, retinal vascular permeability, and tumour activity [5].
PEDF is responsible for the antiangiogenesis in various ocu-
larcompartments[6].Thesesigniﬁcantantiangiogenicprop-
erties led the scientists to shift focus on to studies examining
thepotentialantitumouractivitiesofPEDF.PEDFexpression
changes in the course of progression of diﬀerent tumour
types [5]. Researchers did a number of studies and showed
that there is opposite relation between PEDF levels, grade
and metastatic potential of prostate tumours [7], pancreatic
adenocarcinoma [8], prostate, melanoma, ovarian, osteosar-
coma, glioma [4], hepatocellular carcinoma [9], and Wilm’s
tumours [10].
The human PEDF gene has been mapped, and it encodes
a 418 amino acid protein [11]. It has an asymmetrical charge
distribution, with a high density of basic residues concen-
tratedononesideandofacidicresiduesontheopposite side.
Negatively charged acidic PEDF binds to collagen, lacks neu-
rotrophic activity, and may confer antiangiogenic properties
(Figure 1). Mutational studies have shown that positively
charged amino acids and negatively-charged amino acids are
responsible for heparin and collagen binding, respectively
[12, 13]. There are three phosphorylation sites identiﬁed
which collectively induce antiangiogenic and neurotrophic
activities. A 34-mer peptide and 44-mer peptide are the two
major functional epitopes identiﬁed (as shown in Figure 2)2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic diagram displaying the functional domains of PEDF. (1) Phosphorylation zones—induce diﬀerent degrees of
antiangiogenic and neurotrophic activity, (2) 34-mer peptide region which has antiangiogenic, blocks cell migration, and induces tumour
cell apoptotic activity, (3) 44-mer peptide region which has neurotrophic and cell diﬀerentiation activity, (4) basic region (positive) which is
necessary for heparin binding, and (5) acidic region (negative) which is responsible for collagen binding and lacks neurotrophic activity.
to date. The 34-mer peptide induces apoptosis, blocks
endothelial cell migration and corneal angiogenesis, whereas
the 44-mer peptide displays neurotrophic function and the
ability to block vascular leakage.
2. Why Use PEDF for Cancer?
PEDF has multiple eﬀects against various types of tumour
cells as will be outlined below. Furthermore, PEDF is known
to inhibit the proliferation and migration of endothelial
cells (ECs) and can also promote apoptosis in ECs [5, 18].
Angiogenesis plays a signiﬁcant role in cancer progression,
promoting growth and metastasis of tumours. Inhibition of
the signals that assist new blood vessel growth in tumour(s)
has become an important target in cancer therapy [2, 3]. The
regulation of angiogenesis involves an inverse relationship
between proangiogenic factors and antiangiogenic factors
[19]. PEDF not only reduces angiogenesis, but also can
increasetumourcellapoptosisanddiﬀerentiation[5,18,20].
These separate functions will be examined in more detail in
turn following the next few introductory sections.
3. Cancer Biology—Initiation, Maintenance,
and Progression
Cancer is the second biggest cause of death in the USA, next
to heart disease [1]. In individuals aged 55 years or above,
78% of all the cancers are being diagnosed. These cancers
involve malfunction of genes which control cell growth and
division, and only 5% of all the cancers are hereditary.
Approximately 11.4 million Americans with a history of
cancer were alive in January 2006, according to The National
Cancer Institute. In 2010, about 1,529,560 new cancer cases
were predicted to be diagnosed, out of which 789,620 are
males and 739,940 are females. More than 1500 people per
day were expected to die in 2010.
Cancer is a clonal disease which can initiate from a single
cell harboring several genetic mutations. Until recently, very
little importance was given to the nature of the cell in which
the initiating mutation occurred in human cancer [21]. In
recent years, it has emerged that perhaps stem cells are the
cells of origin for several types of cancer and studies suggest
that a stem cell constitutes the target cell in an increasing
number of human solid tumours. In favour of the above
notion is the ﬁnding that not only some leukaemias but also
epithelialtumourscanoriginateinnormalstemcells(NSCs),
and that carcinomas arise after the accumulation of multiple
oncogenic events acquired after long periods of time [21].
The majority of cancers occur as a result of alterations in
oncogenes. Among these, gene mutation, ampliﬁcation, or
overexpression of HER2/Neu (ErbB2) and epidermal growth
factor receptor (EGFR, ErbB1) have been found in various
humancancers[22].Oncogenesencodeproteinsthatcontrol
cell proliferation, apoptosis, or both. They can be activated
by structural genetic alterations resulting from mutation
or gene fusion. For instance, studies of cytogenetics and
allelotyping on fresh tumours and cancer cell lines revealed
that allelic losses, genetic mutations, and deletions have been
found in the 3p21.3 region, which suggests that one or
more putative genes (tumour suppressor genes) were being
mutated and leading to various types of cancer [23]. Initia-
tion of most types of cancer is mainly due to the functional
loss of a tumour-suppressor gene, followed by alterations
in oncogenes and additional tumour-suppressor genes [24].
This, in essence, forms the basis of the multihit hypothesis of
cancer initiation.
4. Tumour Angiogenesis
The mechanism which involves the growth of new blood ves-
sels from the preexisting blood vessels is called angiogenesis.
Via the action of protein factors produced from a tumour
in a hypoxic environment, endothelial cells of preexistingJournal of Biomedicine and Biotechnology 3
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Figure 2:PEDFapoptoticpathways.Thisschematicchartofapoptoticpathwaysrepresentsconciseinformationfromvarioussources[5,14–
17]. PEDF apoptotic pathways. PEDF has been noted to induce apoptosis in mammalian cells via these pathways. It can directly stimulate
Bax activity, inhibit Bcl-2, signal through PPARγ to activate p53, signal through p38, FasL, and ﬁnally through JNK to block c-FLIP. All these
pathways culminate in apoptosis.
capillaries acquire a tip cell phenotype [25]. Movement of
endothelial tip cells is directed towards incremental levels of
growth factors such as VEGF (vascular endothelial growth
factor), which has a triple-pronged role:
(1) triggering the permeability of the capillaries and
activation of the tip cell phenotype,
(2) promoting migration of tip cells, and
(3) promoting the proliferation and survival of the stalk
ECs.
Migration of tip cells is accompanied by the production
of extracellular MMPs (matrix metalloproteinases) which
are responsible for the remodeling of the nearby ECM
(extracellular matrix). It aﬀects the aﬃnity of VEGF species
atdiﬀerentextracellularlocations.VEGFshavevarietyofiso-
forms which are attached to negatively charged molecules in
the ECM, and MMPs somewhat control the balance of these
VEGF species. For the creation of a functional capillary net-
work and for the determination of speciﬁc vascular patterns,
the presence of isoforms with diverse capabilities is essential.
AftergenerationofapathbythetipcellsintheECM,inorder
t of o r man e wl u m e nf o rb l o o dc i r c u l a t i o n ,ar e o r i e n t a t i o n
of the proliferating ECs is required, in precise coordina-
tion with pericytes and other stromal components [25].
Further processes such as anastomosis (linkage of diﬀerent
branches on the network), the action of pressure forces and
the intrinsic mechanical properties of the tissue, contribute
to the formation of the new vessel network and are ﬁnely
tuned to determine vascular patterning [26]. Hypoxia-
inducible factor-1 (HIF-1) production leads to increased
VEGF transcription, which causes increased vessel perme-
ability and EC migration and proliferation.
Apart from VEGF, there are many other growth fac-
tors responsible for angiogenesis, but VEGF is the most
important of all the factors. Hypoxia occurs as the tumour
outgrows its existing vascular supply [27]. HIF-1 (hypoxia-
inducible factor 1) production only leads to increased pro-
duction of other proangiogenic molecules such as platelet-
derived growth factor (PDGF), transforming growth factors
(TGFs) alpha and beta, basic ﬁbroblast growth factor
(bFGF), angiotensin, ephrins, thrombospondin-1 (TSP-1),
and a class of protein growth factors called angiopoietins
(Ang) [28, 29]. VEGF administration can initiate vessel for-
mation in adult animals, but by itself promotes formation of
only leaky, immature and unstable vessels. In contrast, Ang1
administration seemingly further stabilises and protects the
adult vasculature, making it resistant to the damage and leak
induced by VEGF or inﬂammatory challenges.
bFGF, a member of the ﬁbroblast growth factor family
plays diverse roles during embryonic development in regula-
tion of cell proliferation, migration [30], and diﬀerentiation.4 Journal of Biomedicine and Biotechnology
Angiopoietin-1(Ang-1) [31]p l a y sas i g n i ﬁ c a n tr o l ea tal a t e r
stage of blood vessel formation. PDGF plays an important
role in normal tissue growth and the pathophysiological pro-
cesses of vascular diseases like atherosclerosis and restenosis
[32]. During the initiation and progression of atheroscle-
rosis, VSMCs are activated by growth factors like PDGF or
cytokines, then proliferate and migrate from the media into
the intimal surface of the vessel, thus facilitating neointimal
formation.
TSP-1 is the ﬁrst naturally occurring angiogenic
inhibitor, which is a multifunctional ECM protein. Down-
regulation of TSP-1 causes tumour growth alteration by
modulating angiogenesis in various types of tumours. It
playsacriticalroleininhibitingangiogenesis,resultinginthe
suppression of tumour growth and experimental metastasis
[33]. The TGF-β pathway occupies a central position in the
signaling networks that control growth and diﬀerentiation.
TGF-β is known to have pleiotropic eﬀects which diﬀer
according to cell state and diﬀerentiation. This includes
regulation of proliferation and apoptosis, and stimulation
of epithelial-mesenchymal transition (EMT) which together
is critical for the development of invasive and metastasis
potential [34].
Angiostatin (38KDa), an internal fragment of plasmino-
gen, is a speciﬁc inhibitor of EC proliferation. Akin to
angiostatin, researchers isolated an angiogenesis inhibitor
named endostatin, a 20kDa carboxyl-terminal fragment of
collagen XVIII. It is a speciﬁc inhibitor for endothelial cell
proliferation and with systemic therapy, causes suppression
oftumour-inducedangiogenesisandinhibitstumourgrowth
[35]. It has been shown that when a combination of angio-
statin and endostatin gene-encoded proteins are delivered to
tumour cells by gene transfer, they can exhibit synergistic
antiangiogenic and antitumour eﬀects [36].
5. CellCyclingandApoptosis inCancer
Thecellcycleplaysasigniﬁcantroleinmanagingtomaintain
multicellular organisms healthy and alive, in which the
parent cell genome undergoes replication and the cell
physicallydividesintodaughtercellviacytokinesis.However,
genomic stability and cancer may occur due to unwanted
mutations caused by some environmental and physiological
events. Cells have evolved certain checkpoints to prevent
these types of mutations to daughter cells and allow DNA
repair mechanism. These checkpoints are controlled by
ATM (ataxia telangiectasia mutated) and ATR (ataxia telang-
iectasia and Rad3-related protein) kinases which activate
downstream eﬀector kinases Chk1 (checkpoint kinase 1) and
Chk2, respectively. Checkpoints will repair damages in most
cases, however if the repair mechanisms cannot repair the
DNA damage, cells are either permanently withdrawn from
the cell cycle or are eliminated by programmed cell death
(apoptosis).Cellsmayreenterthecellcycleinaprocesscalled
checkpoint recovery [37]. It is known that programmed cell
death, that is, apoptosis, is required for normal development
of multicellular organisms, whereby unwanted cells are
eliminated during physiological and certain pathological
conditions.
Apoptosis is a programmed cell death event which
occurs during embryogenesis, metamorphosis, endocrine-
dependent tissue atrophy, and normal tissue turnover. In
multicellular organisms, it is responsible for development,
tissue homeostasis, and the immune response via two path-
ways[38].Theyare(i)anintrinsicpathway,whichisinitiated
when the cell is severely damaged, and (ii) the extrinsic
pathway, activated when extracellular death ligands are
bound by their cognate membrane-associated death recep-
tors.
However,ifthereisafaultinapoptosisitleadstonumber
of serious diseases including cancer, autoimmunity, and
neurodegeneration [39]. When genetically unstable cancer
cells tend to acclimatise to a tissue microenvironment that is
distant from the primary tumour, a process called metastasis
occurs [40]. Metastasis requires the cancer cells to detach
from the primary tumour mass, move to and invade blood
vessels, survive within the circulation, attach to the endothe-
lium of distant organs, penetrate the endothelial barrier, and
establish new tumour colonies. It is this multistage process
which is the primary cause of cancer-related deaths, with
the primary tumour often resectable. PEDF is responsible
for apoptosis of ECs either through the p38/MAPK pathway
[14] or through the Fas/FasL pathway [41]. (Detailed PEDF-
mediated apoptotic pathways are provided in Figure 2).
6.PEDFand Antiangiogenesis
Angiogenesis is the process by which new blood vessels are
formed from a preexisting microvascular network, and it
plays a major role in tumour growth and metastasis. For
evaluating antitumour eﬃcacy, Yang et al. [42]c o n s t r u c t e d
PEDF expressing-adenovirus (Ad-PEDF), and with success-
fultransferofthePEDFgene,antitumoureﬃcacyinamouse
tumour model was tested. The tumour volume was inhibited
(2195.1 ± 462.9mm 3 approximately 50%) with Ad-PEDF
when compared to the controls. The mouse which was inoc-
ulated with Ad-PEDF showed a 50% survival rate at day 38,
than controls (50% on day 13). By using TUNEL (terminal
deoxynucleotidyl transferase dUTP nick end labeling) assay,
it was determined that the apoptosis index in tumour tissue
was higher (26.3%±3.3%) in the Ad-PEDF group than
control groups (6.3%±4.7% and 5.6%±1.9%), conﬁrming
that increased apoptosis caused the accompanying decreased
tumour volume. For elucidating whether the increase in
apoptosis of Ad-PEDF-treated tumour tissue was associated
with the antiangiogenic eﬀect of PEDF, scientists analysed
microvesseldensity(MVD)oftumourtissuesandfoundthat
Ad-PEDF demonstrated signiﬁcant decrease in MVD when
compared to control groups.
In[43]determinedthegrowthcharacteristicsofahuman
malignant melanoma cell line overexpressing human PEDF
in vitro and in vivo. In contrast to the empty vector-
transfected group, PEDF overexpression completely inhib-
ited the growth of the tumour. TUNEL assay was performed
to determine the extent of apoptosis in the PEDF-transfectedJournal of Biomedicine and Biotechnology 5
andcontrolvector-transfectedtumoursanditwasfoundthat
apoptotic cells increased 30% in the tumours derived from
the PEDF-overexpressing G361 cells, when compared with
control vector-transfected tumour cells.
In this study, Garcia et al. [44] determined the results
of overexpression of PEDF on both melanoma primary
tumourgrowthandmetastasisdevelopment.Overexpression
by melanoma cells inhibited subcutaneous tumour forma-
tion. After tail vein injection, PEDF-overexpressing human
melanoma cells were unable to grow and metastasise to the
lung and liver. The authors also determined the eﬀect of
PEDF on proliferation and apoptosis in the subcutaneous
tumours and found tumour growth collapse, likely due
to impaired vascularisation. PEDF-positive melanoma cells
showed signiﬁcantly lower chemotaxis in a modiﬁed Boyden
chamber assay. Quantitative data analysis showed a 3- to
5 - f o l dr e d u c t i o ni nm i g r a t i o na n di n v a s i v e n e s so fP E D F
positive cells.
A metabolite isolated from ginseng protopanaxadiol
saponins called compound K (CK; 20-O-beta-D-gluco-
pyranosyl-20(S)-protopanaxadiol) has an ability to induce
apoptosis in various types of cancers. Based on this, Jeong
et al. [45] evaluated the antiangiogenic eﬀects of CK in vitro
and in vivo. bFGF induces angiogenesis in human umbilical
vein ECs (HUVECs). In vitro tests determined that CK
inhibited bFGF-induced proliferation, migration and tube
formation. In vivo antiangiogenic activity of CK was eval-
uated by a Matrigel plug assay and it was found that CK
inhibited bFGF-induced angiogenesis. By measuring the
levels of VEGF and PEDF, Jeong et al. evaluated the eﬀect
of CK on the phosphorylation of p38/MAPK, and AKT in
bFGF-treated HUVECs and found decreased levels of VEGF
and increased levels of PEDF following CK treatment. These
ﬁndings suggest that there is a relationship between PEDF,
VEGF, and bFGF with respect to angiogenesis.
7. PEDFandTumour CellDifferentiation
Angiogenesis underlies the processes of bone growth, repair,
and remodelling and may account at least in part for the
aggressive nature of osteosarcoma [46]. PEDF regulates
angiogenesis to underlie the physiological processes of bone
formation,growth,andremodelling[47].Anelegantbalance
exists between proangiogenic and antiangiogenic factors in
bone so that the degree of vascularisation is appropriate
for the biology required. VEGF is widely regarded as the
most important proangiogenic factor, while PEDF has been
identiﬁed as the most-potent antiangiogenic factor [18]. The
balance between these two factors is as important in bone
physiology as it is in other tissues.
PEDF was found to be expressed in the zones of active
bone formation and its role in cell diﬀerentiation as well as
the maintenance of high growth rates in the mesenchymal
cell layer was determined by Lord et al. [48] using a deer
antler model. Tombran-Tink and Barnstable hypothesized
about the signiﬁcance of PEDF in bone based on RT-PCR
and western blot analysis [14], and more recent studies [49]
demonstrated that PEDF inhibits osteoclast formation,
survival and bone resorption function, and eﬀects were
abrogated by VEGF.
PEDFexpressionbyosteoblastsandosteoclastsinregions
of active bone formation regulates neovascularisation at
these sites, a process that underlies bone formation, growth
and remodelling. Without a supporting vasculature, bone
precursors are unable to localise to those sites intended for
bone development [50]. Angiogenesis in the ossiﬁcation and
lower hypertrophic zones is necessary for the continued
growth and functioning of osteoblasts and osteoclasts,
enabling the replacement of cartilaginous tissue by bone,
a process ultimately regulated by a balance between PEDF
and VEGF [47]. Using immunohistochemistry and in situ
hybridisation, PEDF expression was shown to be largely
restricted to the chondrocytes of the avascular resting,
proliferative and upper hypertrophic layers of the epiphysis,
and to regions of active bone remodelling.
In vitro and in vivo studies have revealed that in the case
of osteosarcoma, PEDF can induce both indirect and direct
suppression of tumour growth and progression by potent
antiangiogenic capability of PEDF targeting tumour vascu-
lature and induction of osteosarcoma cell apoptosis, diﬀer-
entiation, and inhibition of cell cycling, respectively [2, 3].
Osteosarcoma usually arises in the metaphysis of long bones.
The epiphyseal plate is found between the epiphysis and
metaphysis of long bones, which is a natural barrier to
tumour invasion. The resistance of epiphyseal cartilage to
osteosarcoma invasion is likely to be due to the diﬀerential
expression of PEDF and VEGF in the zones of the epiphysis
[51].
Metastasis is the foremost problem in the treatment of
osteosarcoma. In vitro studies with rPEDF revealed dose-
dependent reduction in cellular invasion by matrigel assay as
well as an increase in cell adhesion to collagen type-1 using
the human SaOS-2 cell line [52]. In vivo studies done on
an orthotopic model [53] showed that treatment with PEDF
had the greatest impact on metastases. There was a 70%
reductioninthedevelopmentofpulmonarymetastasesanda
40% reduction in primary tumour size in those mice treated
with PEDF [52]. More recently, sustained administration of
PEDF via osmotic pumps implanted in mice bearing SaOS-2
tumours demonstrated reduced metastasis to the lungs [54].
Notably, treatment with PEDF was delayed until after the
macroscopic appearance of primary tumours. Thus, in this
study, both the model used and the delivery regimen were
close to the appropriate clinical treatment foreseeable in the
future if PEDF is to be used as an osteosarcoma therapeutic.
The critical role of PEDF in regulating MMP activity
makes the area of metastasis an intriguing one. Initially,
it was found that PEDF can signiﬁcantly downregulate the
levels of MMP-14 but not MMP-2 and -9 in a human
chondrosarcoma cell line [55]. This was corroborated by a
decreased invasion of cells through collagen-1 matrix in the
presence of PEDF. Human melanoma cells were partially
inhibited in their invasion, with reduced traﬃcking of
membrane-bound MMP-14 to the cell surface [56].
In [57] demonstrated the ability of PEDF as a multi-
functionalantitumouragentinneuroblastomasbyinhibiting
tumour angiogenesis and diﬀerentiating tumour cells to6 Journal of Biomedicine and Biotechnology
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Figure 3: Types of cancers that PEDF has activity against.
produce PEDF. rPEDF cells were injected into the neuroblas-
toma tumours in vivo. After histological examination, PEDF-
treated tumour samples resulted in pale regions correspond-
ing to conﬂuent areas of spindle-shaped cells which are char-
acterised by bland nuclei with abundant cytoplasm. These
c e l l sw e r er e l a t i v e l yd i ﬀerent from the more primitive neu-
roblasts observed within the tumour distant from the injec-
tion site. The control treatments were composed of undif-
ferentiated neuroblast cells. The authors concluded that even
a reduced treatment regimen with PEDF in vivo was capable
to promote discrete areas of tumour cell diﬀerentiation.
8.PEDFandDirectTumourCellInhibition
Most of the human ovarian cancers are derived from the
ovarian surface epithelium (OSE), which is made of simple
squamous to cuboidal mesothelial cells. In one study,
Cheung et al. [58] demonstrated the role of PEDF in tumori-
genesis of ovarian cancer in vitro. MTT cell viability and
proliferation assay were performed to determine the physi-
ological functions of PEDF. The treatment with recombinant
PEDF (rPEDF) resulted in a dose-dependent decrease in
cell growth and concomitant increase in apoptosis, when
comparedwithcontrols.TheroleofendogenousPEDFinthe
regulation of cell proliferation and viability was determined
by RNA interference. This study is the ﬁrst to explain the role
of PEDF in OSE biology and ovarian cancer and suggested
that the loss of PEDF may be of relevance in carcinogenesis.
In another study, human pancreatic adenocarcinoma cell
lines were stably transfected with PEDF [59], and the eﬀects
of overexpression investigated in a murine subcutaneous
tumour model. Overexpression with a lentivirus-PEDF (LV-
PEDF) vector resulted in 28 and 61% inhibition of prolif-
eration and migration of cells, respectively. PEDF overex-
pression was evaluated in vivo and treatment signiﬁcantly
suppressed tumour growth and peritoneal metastasis.
PEDF can suppress osteosarcoma growth, angiogenesis,
and metastasis by its multitargeted antitumour activities
both in vitro and in vivo [51]. The in vitro anti-proliferative
eﬀect was evaluated on two osteosarcoma cell lines rat UMR
106-01 and human SaOS-2 and resulted in dose-dependent
reduction in cell proliferation. Varying concentrations of
rPEDF were used to determine whether rPEDF induced
apoptosis in osteosarcoma, and then analysed by TUNEL
assay to determine the percentage of cells undergoing apop-
tosis and found that rPEDF signiﬁcantly increased apoptosis
and suppressed proliferation of cells. An orthotopic SaOS-
2t u m o u rm o d e l[ 53], consisting of cells injected into the
proximal tibiae of nude mice and co-administered with
rPEDF showed a signiﬁcant reduction in primary tumour
size, growth rates and a signiﬁcant reduction in pulmonary
metastases.
Osteosarcoma, a prominent primary bone tumour, rep-
resents the second highest cause of cancer-related death in
childhood and adolescence. Ek et al. [52] demonstrated the
potential of plasmid mediated gene transfer of PEDF for
direct inhibition of tumour growth, angiogenesis and metas-
tasis in two clinically relevant orthotopic models of osteosar-
coma (rat UMR 106-01 and human SaOS-2) via both in vitro
and in vivo. The team examined whether PEDF overex-
pression inﬂuences in vivo primary tumour growth and
the development of pulmonary metastasis. UMRPEDF (PEDF
overexpression)tumoursdemonstratedslowergrowthkinet-
ics compared to the parental and vector groups; with a
two- to threefold reduction in tumour growth and SaOSPEDF
tumours were 59% smaller, respectively. While all mice in
the control groups developed lung metastases, only 20% of
mice with UMRPEDF tumours and no mice with SaOSPEDF
tumours developed pulmonary metastases. Immunohisto-
chemical staining of the tumour microvascular ECs with an
antibody against CD34 evaluated that a signiﬁcant reduction
in MVD (microvessel density) in both PEDF-overexpressing
tumour groups with an 85 and 74% decrease seen in the
UMRPEDF and SaOSPEDF groups, respectively.
PEDF is known as a multifunctional protein which
possesses potent antiangiogenic, neurotrophic, neuropro-
tective, immunosuppressive, and antitumorigenic properties
(see Figure 3). Ek et al. [60] identiﬁed potential functional
epitopesonthePEDFproteinsequenceanddeterminedtheir
antitumour activity in the human osteosarcoma cell line
SaOS-2. They characterized the bioactivity of four synthetic
peptides corresponding to sequences 40–64 (StVOrth-1),
78–102 (StVOrth-2), 90–114 (StVOrth-3), and 387–411
(StVOrth-4) of human PEDF using SaOS-2. They evaluated
the antiproliferative eﬀects of the peptides and found that
StVOrth-2 exhibited the most signiﬁcant anti-proliferative
activity, with a reduction of 59% and 63% seen at day 5 with
lower (5nM) and higher (25nM) concentrations, respec-
tively. They examined the potential behind suppression ofJournal of Biomedicine and Biotechnology 7
tumour cell invasion through Matrigel and found that all
four peptides signiﬁcantly decreased Matrigel invasion by
greater that 50%. However StVOrth-4 provided that most
consistent inhibition, with greater than 70% reduction
observed at all concentrations. Ek et al. examined treatment
with the PEDF-derived peptides for understanding the alter-
ation of osteosarcoma cell adhesion to collagen (a potential
mechanism in antimetastasis) and found that all four pep-
tides considerably increased cell adhesion to collagen type 1,
with StVOrth-3 demonstrating 53% greater ability than the
other peptides. Prodiﬀerentiation potential studies of the
PEDF fragments in vitro revealed that administration of
StVOrth-1, -2, and -3 signiﬁcantly increased nodule forma-
tioninSaOS-2cells.Theyfurthertestedthe invivoactivityof
StVOrth-2 and StVOrth-3 in an orthotopic model of human
osteosarcoma, using a model employing tumour cells pre-
mixed withpeptides, then injected orthotopically. StVOrth-2
exhibited predominantly antiproliferation activity, while
StVOrth-3 caused mainly increased collagen adhesion and
VEGF suppression. The results of an eﬃcacy study using
sustained delivery of peptides in the orthotopic model of
osteosarcoma is included in this issue [5, 54].
Inamorerecentstudy ,Mirochniketal.[61]havedemon-
strated improved antiangiogenic activity by the small PEDF
peptide, only 18mer in length, called P18. P18 inhibited the
growth of prostate tumour growth and the more aggressive
Renca cells in vivo in the subcutaneous xenograft model at
10mg/kg. At the same dose, the 34-mer had no signiﬁcant
eﬀect on tumour growth. The authors stated that P18 was
more potent at blocking tumor angiogenesis and causing
higher levels of intratumoral apoptosis.
9. FutureDirections
PEDF is a promising therapeutic agent for various types
of cancers. Until now it is known that it is capable of
reducing cancer via inhibiting angiogenesis, tumour growth,
cell migration and inducing apoptosis and tumour cell dif-
ferentiation. Only a little is known about the proangiogenic
factors like VEGF, bFGF, PDGF, and there is lot to be known
about other proangiogenic factors that interact with PEDF.
The fact that regions of PEDF have diﬀerent functional
activity may lead to synthesis of small and cheap peptides
which can be tested as anticancer drugs in the near future.
Recent biochemical studies have provided some insight into
PEDFstructureandfunction.However,veryfewarticleshave
lookedatPEDFreceptor-mediatedsignallingincancer.Some
receptors (G-protein-coupled receptor GPR39) can protect
cells from death by increasing secretion of PEDF [62]. More
work has to be done in this area given that more than two
receptors for this protein have been found to date.
10. Summary
Cancer is characterized by uncontrolled growth and spread
of abnormal cells. PEDF is known to be a multifunctional
protein which possesses potent antiangiogenic,
neurotrophic, neuroprotective, immunosuppressive, and
antitumorigenic properties. Scientists designed Ad-PEDF
for evaluating the antitumour eﬃcacy and demonstrated
role of PEDF in apoptosis and angiogenesis. Other group
of researchers demonstrated that overexpression of PEDF
suppressed tumour growth and angiogenesis and enhanced
the rate of apoptosis. PEDF regulation of angiogenesis
underlies the physiological processes of bone formation,
growth and remodelling. PEDF can induce both indirect and
direct suppression of tumour growth and progression by
potent antiangiogenic capability. An orthotopic model of
osteosarcoma studies showed that treatment with PEDF had
the greatest impact on metastases. There is now justiﬁcation
for evaluation of PEDF eﬃcacy in other types of cancers.
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